Abstract
Poliovirus caused several major epidemics in the early 1950's that resulted in about 21,000 cases per year in the United States. In 1955, an inactivated polio vaccine was developed that limited the spread of this feared disease. The Salk vaccine, combined with a live virus vaccine produced by Sabin, plus a comprehensive eradication campaign, have eliminated wild type poliomyelitis in the United States. However, there remain many patients who suffer from the sequelae of this disease through permanent paralysis and post-polio syndrome.
| Original language | English (US) |
|---|---|
| Title of host publication | xPharm |
| Subtitle of host publication | The Comprehensive Pharmacology Reference |
| Publisher | Elsevier Inc. |
| Pages | 1-4 |
| Number of pages | 4 |
| ISBN (Print) | 9780080552323 |
| DOIs | |
| State | Published - Dec 1 2011 |
All Science Journal Classification (ASJC) codes
- Pharmacology, Toxicology and Pharmaceutics(all)
Fingerprint Dive into the research topics of 'Poliomyelitis'. Together they form a unique fingerprint.
Cite this
Vander, E. T., Gentry-Nielsen, M., & Knoop, F. C. (2011). Poliomyelitis. In xPharm: The Comprehensive Pharmacology Reference (pp. 1-4). Elsevier Inc.. https://doi.org/10.1016/B978-008055232-3.60926-2